Separating predictive genetic testing from snake oil: regulation, liabilities, and lost opportunities.
This article explores the extent to which completion of maps of the human genome, coupled with the introduction of technology that will accelerate the identification of gene and protein function, have introduced immeasurable potential to advance life science and health care through genetic profiling. In light of definitional uncertainty, the regulatory and legal environment surrounding predictive genetic testing threatens to impede clinical utilization of genetic profiling technologies that could significantly improve human health. Especially given that genetic testing technologies have been stigmatized in the public and medical community, they must enter the marketplace with a regulatory framework that assures safety, efficacy, and market responsibility.
Malinowski
M J
MJ
Widener University School of Law, USA.
D001709:Biotechnology / Q000331:legislation & jurisprudence; D019295:Computational Biology; D030661:Genetic Privacy; D005820:Genetic Testing / Q000191:economics / Q000331:legislation & jurisprudence* / Q000592:standards*; D033161:Government Regulation; D006801:Humans; D010597:Pharmacogenetics; D011785:Quality Assurance, Health Care; D014481:United States; D014486:United States Food and Drug Administration